Clinical practice status of the adjuvant therapy in hepatocellular carcinoma (HCC): A survey of Chinese hepatobiliary surgeons.
Hui‐Chuan Sun(Fudan University), Haiqing Wang(University of Electronic Science and Technology of China), Tianfu Wen(Sichuan University), Lianxin Liu(University of Science and Technology of China), Zhixian Hong(Chinese PLA General Hospital), Jie Gao(Peking University), Xin‐Rong Yang(Sun Yat-sen University), Xinyu Bi(Chinese Academy of Medical Sciences & Peking Union Medical College), Changzhen Shang(Sun Yat-sen University), Ying–Hong Shi(Ministry of Education of the People's Republic of China), Kui Wang(Shihezi University), Jun Li(Tongji University), Lu Wang(Tianjin Medical University), Jia Fan(Sun Yat-sen University), Xin Zheng(Capital Medical University), Li Xu(Fujian Medical University), Zhiyong Huang(Tongji Hospital), Minshan Chen(Sun Yat-sen University), Jian Zhou(Shandong University)
Cited by 1
Related Papers
Global patterns of hepatocellular carcinoma management from diagnosis to death: the <scp>BRIDGE</scp> Study
|Liver International|2015|1.3k
Proteomics identifies new therapeutic targets of early-stage hepatocellular carcinoma
|Nature|2019|982
Plasma MicroRNA Panel to Diagnose Hepatitis B Virus–Related Hepatocellular Carcinoma
|Journal of Clinical Oncology|2011|644
Adjuvant Transarterial Chemoembolization for HBV-Related Hepatocellular Carcinoma After Resection: A Randomized Controlled Study
|Clinical Cancer Research|2018|355